Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 2/3 clinical study of HLX22 in combination with HLX87 for injection, according to a Feb. 27 Hong Kong bourse filing.
Shares of the drugmaker were down nearly 3% in Monday afternoon trading.
The trial studies the use of the drug for the first-line treatment of patients with HER2-positive recurrent or metastatic breast cancer in Mainland China, excluding Hong Kong, Macau, and Taiwan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.